MacroGenics announced the initiation of the PARADIGM trial, a Phase 2 study evaluating MGAWN1 (humanized monoclonal antibody) for the treatment of individuals with suspected central nervous system infection due to West Nile Virus (WNV). PARADIGM is a randomized, double-blind, multicenter, placebo-controlled trial designed to evaluate the safety and efficacy of MGAWN1 in patients ≥18 years of age with signs and symptoms of acute West Nile Neuroinvasive Disease.

MGAWN1 specifically recognizes the envelope (E) protein of WNV to exhibit potent neutralizing and fusion-inhibitory activity against WNV in laboratory studies conducted in vitro and in vivo.

For more information call (301) 251-5172 or visit www.macrogenics.com.